KANGGANRAN YAOXUE

Archive

  • 2023 Volume 20 Issue 10
    Published: 25 October 2023
      
  • Select all
    |
  • Status of Application and Development and Prospect of Oxazolidinone Antituberculosis Drugs*1
    LU Yu
    2023, 20(10): 1013-1017. https://doi.org/10.13493/j.issn.1672-7878.2023.10-003
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Oxazolidinones are a class of antibacterial drugs with strong antibacterial activity against gram-positive pathogens, and many of them also have good antibacterial activity against Mycobacterium tuberculosis, and linezolid, for example, has good therapeutic effect on drug-resistant or even multi-drug resistant tuberculosis. However, the myosuppressive effect of linezolid limits its wide application in anti-tuberculosis therapy to some extent, so the research and development of highly effective and low-toxicity oxazolidinones has attracted much attention. In this paper, the clinical application of linezolid in anti-tuberculosis and the clinical development status of other oxazolidinones are reviewed, so as to deepen the understanding of the anti-tuberculosis effect of oxazolidinones.
  • Application Prospect of Contezolid in Anti-tuberculosis Treatment*1
    Bao Zi-wei, Liu Jia, Yao Lin, WU Mei-ying
    2023, 20(10): 1018-1024. https://doi.org/10.13493/j.issn.1672-7878.2023.10-004
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Presently, the global situation of tuberculosis prevention and treatment is not optimistic, with high morbidity and mortality. China is still one of the countries with a high burden of tuberculosis in the world. In recent years, as a representative of oxazolidinone drugs, linezolid has been widely used in the treatment of drug-resistant and severe tuberculosis, and its clinical status has been continuously improved due to its outstanding antibacterial effect. However, because of problems such as myelosuppression, neurotoxicity, lactic acidosis, potential drug-drug interactions, and narrow therapeutic windows, etc., the shortcomings of linezolid in long-term anti-tuberculosis treatment have become increasingly prominent. Contezolid, a new generation of oxazolidinone drug, has the antibacterial activity equivalent to or even stronger than linezolid, and has lower risks of myelosuppressive toxicity, neurotoxicity, and lactic acidosis, a unique metabolic pathway, and good pharmacokinetic profiles, so it has gradually attracted attention of clinical professionals. This article reviews the current situation of tuberculosis prevention and treatment, the status and challenges of linezolid in tuberculosis treatment, as well as the pharmaceutical characteristics of contezolid and experimental research and clinical exploration in anti-tuberculosis, so as to provide reference for the subsequent further studies of contezolid in drug-resistant tuberculosis and severe tuberculosis.
  • Consensus on Linezolid in the Treatment of Tuberculosis(2022 update)(reprinted)*1
    Chinese Society for Tuberculosis, Chinese Medical Association
    2023, 20(10): 1025-1032. https://doi.org/10.3760/cma.j.cn112147-20220320-00220
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Linezolid is the core drug for the treatment of multidrug-resistant tuberculosis. In 2018, Chinese Society for Tuberculosis, Chinese Medical Association (CSTB) issued a "consensus on linezolid in the treatment of tuberculosis". With the wider use of it in clinic, the improved understanding and the progress in research, CSTB organized experts to update this consensus and formed "consensus on linezolid in the treatment of tuberculosis(2022 update)", with a view to play a guiding role for clinicians. The consensus included the molecular structure and mechanism of action, pharmacodynamics, pharmacokinetics, clinical application, indications, contraindications and relative contraindications, dosage, usage and formulation of chemotherapy regimen, adverse reactions and clinical application. In this edition, we updated the drug resistance mechanism of linezolid, and the medical evidence was rated and recommended according to the grading of recommendations assessment, development and evaluation (GRADE) method.
  • Research Progress in Novel Anti-Tuberculosis Chemical Drugs*1
    YANG Guo-ling, SHA Wei
    2023, 20(10): 1033-1041. https://doi.org/10.13493/j.issn.1672-7878.2023.10-006
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Tuberculosis is a chronic infectious disease caused by mycobacterium tuberculosis infection, which can invade various organs of the human body. Pulmonary tuberculosis is the most common disease and is one of the main causes of death worldwide. With the abuse of antibiotics and non-standardized use of anti-tuberculosis drugs, drug-resistant tuberculosis continues to emerge, and the treatment regimens for drug-resistant tuberculosis are complex, with the problems of long medication courses and many adverse drug reactions, etc., which brings great challenge to the clinical work. Therefore, there is an urgent clinical need for new drugs that are effective against mycobacterium tuberculosis infections, especially infections caused by drug-resistant strains. This article first describes the effectiveness and safety data of marketed drugs, and then elaborates the new drugs that are currently in the clinical research stage based on the main effect targets of the drugs (the cell wall of mycobacterium tuberculosis, protein synthesis, energy metabolism, DNA synthesis, etc.).
  • Interpretation of Treatment Guidelines for Drug-susceptible Tuberculosis in Children*1
    WANG Ze-ming, SHEN A-dong
    2023, 20(10): 1041-1046. https://doi.org/10.13493/j.issn.1672-7878.2023.10-007
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    WHO recommended treatment regimens in 6 to 12 months for drug-susceptible tuberculosis (DS-TB) in children in 2010 and 2014 respectively. In recent years, with the widespread implementation of the treatment regimens, it has been found in clinical practice that poor compliance caused by a long treatment course of the treatment regimen is an important factor affecting children to complete the entire treatment process. With the completion of a phase III clinical trial on the short-course treatment regimen and the research on chemotherapeutic regimens for children and adolescents with susceptible tuberculosis in different countries, the evidence-based basis has gradually increased. In 2022, WHO issued a new version of the Guidelines on Management of Tuberculosis in Children and Adolescents, integrating the latest recommendations with 2014 Guidelines and replacing 2014 Guidelines. The Guidelines expound the treatment regimens for drug-susceptible tuberculosis and extrapulmonary tuberculosis, and severe and non-severe tuberculosis in children in details, and recommend for the first time the 6-month tuberculous meningitis intensification plan and the 4-month non-severe tuberculosis treatment regimen with a shorter course of treatment. By combining the new WHO Guidelines, this article gives in-depth interpretation of treatment on DS-TB in children, which facilitates pediatric clinicians to effectively manage tuberculosis in children.
  • Research Progress in Influencing Factors of Liver Injury Caused by Anti-tuberculosis Drugs*1
    CHEN Mu-xing, WU Di, LIN You-fei, CHEN Xiao-hong
    2023, 20(10): 1046-1050. https://doi.org/10.13493/j.issn.1672-7878.2023.10-008
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    China is a country with a high burden of tuberculosis, that is, with a large number of tuberculosis patients, and a long period of anti-tuberculosis treatment. In the course of anti-tuberculosis treatment, various adverse drug reactions may occur due to complex and diverse combination of drugs, of which drug-induced liver injury (DILI) is the most common and most harmful one, with mild cases showing transient elevated transaminases and severe cases leading to liver failure and even life-threatening effects. Therefore, some patients have to discontinue anti-tuberculosis treatment. This article reviews the influencing factors of anti-tuberculous drug-induced liver injury (ATB-DILI) in patients from aspects such as living habits, underlying diseases, and genetic factors, providing reference for prevention and treatment of ATB-DILI in clinical practice.
  • Research Progress of Thymosin α1 in Tuberculosis Immunotherapy*1
    TAN Zhuo-lin, ZENG Jia-wei
    2023, 20(10): 1051-1055. https://doi.org/10.13493/j.issn.1672-7878.2023.10-009
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Mycobacterium tuberculosis can resist immune damage of the host through an immune escape pathway and cause a low immune function of the host, suggesting that tuberculosis patients have impaired immune functions to varying degrees. The immunotherapy can improve the patients' immune functions with good safety; when it is combined with anti-tuberculosis chemotherapy drugs, positive clinical benefits can be achieved. Among them, thymosin α1, as a classic immunomodulator, has been used in tuberculosis patients in China. This article reviews the research progress of thymosin α1 in tuberculosis immunotherapy.
  • Pharmaceutical Care of Anti-infective Treatment in a Patient with Multidrug-resistant Non-tuberculous Mycobacterium Lung Disease*1
    YU Xiu-heng, XIE Yu-qing, LONG You-qi, ZHAO Yu
    2023, 20(10): 1056-1061. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0010
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaceutical care process of anti-infective treatment in a patient with multidrug-resistant non-tuberculous mycobacterium lung disease, so as to provide reference for the treatment of such patients. Methods: After analyzing the drug susceptibility test report of a patient with multidrug-resistant non-tuberculous mycobacterium lung disease, the clinical pharmacist suggested another drug susceptibility test according to the drug susceptibility test standards of non-tuberculous mycobacterium (NTM). Through a combination with the drug pharmacokinetic characteristics, the treatment regimen was adjusted from cefoxitin + imipenem/cilastatin sodium + ethambutol + clarithromycin to cefoxitin + imipenem/cilastatin sodium + amikacin nebulized inhalation + azithromycin + tigecycline, improving the condition of the patient after 20 days of treatment. According to the drug susceptibility test results of NTM, the anti-infective treatment regimen was adjusted to cefoxitin + amikacin + azithromycin + tigecycline + moxifloxacin based on the patient's condition, after 20 days of treatment, the patient was discharged under further improved condition and was transferred to a community hospital for further treatment. The clinical pharmacist also participated in evaluating and preventing adverse drug reactions in the treatment process, and provided medication guidance for the patient after discharge. Results: The physician followed the advice of the clinical pharmacist and adjusted the treatment regimen twice. After 3 months of treatment, the patient's condition was well controlled and no serious adverse reactions occurred. Conclusion: The clinical pharmacist has participated in the diagnosis and treatment process of a patient with multidrug-resistant non-tuberculous mycobacterium lung disease, developed personalized anti-infective treatment regimens for the patient, and achieved good effects, reflecting the professional ability and service level of the clinical pharmacist, and providing ideas for the clinical diagnosis and treatment of multidrug-resistant non-tuberculous mycobacterium lung disease.
  • Pharmaceutical Care of Hemoptysis Treatment in a Pulmonary Tuberculosis Patient Complicated with Coronary Heart Disease
    CHEN Gui-fang, QIAN Xin
    2023, 20(10): 1061-1065. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0011
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaceutical care process of hemoptysis treatment in a pulmonary tuberculosis patient complicated with coronary heart disease, so as to provide reference for the treatment of such diseases. Methods: A patient with pulmonary tuberculosis was admitted for treatment due to "intermittent coughing and hemoptysis for more than 6 hours". The patient has received relatively regular anti-tuberculosis treatment, and underwent coronary stent implantation due to coronary heart disease two months ago. After the surgery, drugs such as aspirin, atorvastatin calcium, ticagrelor, and metoprolol succinate were taken regularly. In addition, the patient also had concomitant bronchiectasis. Results: Through reviewing relevant information and combining the patient's actual situation, the clinical pharmacist believed that the patient's hemoptysis may be related to the use of antiplatelet drugs and bronchiectasis, and after consultation with the doctor, aspirin and ticagrelor were discontinued, and clopidogrel was used instead. After treatment, the patient's hemoptysis symptoms improved significantly. Conclusion: Clinical pharmacists provide pharmaceutical services, optimize drug treatment regimens for patients, and improve the effectiveness and safety of medication.
  • Pharmaceutical Practice of Anti-Tuberculosis Treatment in One Patient with Drug-Induced Liver Injury Caused by Immune Checkpoint Inhibitors*1
    ZHANG Qian, FANG Shi-rong, WANG Ya-li
    2023, 20(10): 1066-1070. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0012
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the pharmaceutical care process of anti-tuberculosis treatment for the patient with drug-induced liver injury (DILI) caused by immune checkpoint inhibitors, and provide reference for clinical anti-tuberculosis treatment of patients with DILI. Methods: One patient with lower esophageal squamous cell carcinoma after surgery showed abnormally elevated levels of alanine aminotransferase (385.47 U/L), alkaline phosphatase (456.59 U/L) and total bilirubin (156.17 μmol/L) during the second course of chemotherapy, with the manifestation of mixed type severe liver injury; during the period, the patient developed symptoms such as cough, expectoration, and fever (39°C), and acid-fast bacilli (+++) were detected in the sputum smear. Combined with the chest CT examination results, the patient was considered to have secondary pulmonary tuberculosis in both lungs. It was recommended to initiate anti-tuberculosis treatment with drugs. Results: After the patient developed liver injury, the clinical pharmacist considered that it was caused by chemotherapy drugs (the RUCAM scores of pembrolizumab, paclitaxel and carboplatin were 6, 5, and 4 respectively), but the drugs were not discontinued. The patient received hepatoprotective treatment with adenoglycine butanesulfonate, polyene phosphatidylcholine, and methylprednisolone on the basis of magnesium isoglycyrrhizinate, however, the liver injury indicators continued to worsen, so all drugs with potential risks of liver injury were discontinued; subsequently, when carrying out anti-tuberculosis treatment, taking into account the patient's current liver injury, the doctor adopted the clinical pharmacist's suggestion and used drugs with a low risk of liver injury such as ethambutol, levofloxacin, and streptomycin; during this period, the patient's liver injury indicators kept improving; and then isoniazid was added and streptomycin was changed to linezolid; one month later, the patient's liver function returned to normal. Conclusion: When patients with severe mixed DILI need to carry out anti-tuberculosis treatment, clinical pharmacists should assist doctors in successfully treating patients with DILI and carrying out anti-tuberculosis treatment based on their professional knowledge and relevant literature reports, to ensure the life health of patients.
  • Pharmaceutical Analysis of Contradictory Phenomena in Patients with Tuberculous Meningitis
    REN Meng, ZHANG Tian-xiang, WU Qian-hong
    2023, 20(10): 1070-1075. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0013
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the treatment and pharmaceutical care process of concurrent contradictions in patients with tuberculous meningitis (TBM), so as to provide reference for clinical management of TBM patients with concurrent contradictions. Methods: The clinical pharmacist participated in the drug treatment process of a case of TBM with concurrent contradictions. By reviewing evidence-based evidence from multiple sources and combining the characteristics of drug blood-brain barrier permeability, appropriate drug composition treatment regimens were selected for the patient, and pharmaceutical care and medication education were conducted. Afterwards, the patient experienced contradictions, and the clinical pharmacist assisted the doctor in analyzing the reasons, providing medication advice again, and implementing pharmaceutical care for the patient. Results: With the participation of the clinical pharmacist in developing the treatment regimens for TBM patients, providing medication reference for contradictory phenomena, the patient's condition was significantly controlled and improved, and the patient was discharged. Conclusion: Clinical pharmacists utilize their professional advantages in pharmacy, exert their subjective initiative, participate in clinical drug treatment, and assist doctors in formulating and optimizing drug treatment regimens, so as to ensure the safety and effectiveness of medication.
  • Establishment of Voriconazole Therapeutic Drug Monitoring Method and Its Application in Tuberculosis Patients Complicated with Fungal Infection
    HAN Ke-qing, WANG Zi-yan, LAI Yong-wei, WU Qian-hong
    2023, 20(10): 1076-1080. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0014
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To establish a method based on ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to determine the concentration of voriconazole in human blood, and apply this method to tuberculosis patients complicated with fungal infection, so as to provide reference for the antifungal treatment of such patients. Methods: The chromatographic column was ACQUITY UPLC® HSS T3 C18 column (2.1 mm × 50 mm, 1.8 μm). The mobile phase was acetonitrile (A)-water (containing 0.1% of formic acid) (B), the gradient elution curve was 6, the flow rate was 0.3 mL/min, gradient elution, with internal standard of gatifloxacin, electric spray ion source, multi-reaction ion monitoring mode, positive ion mode detection, voriconazole and gatifloxacin ion pair m/z as 350.138/127.08 and 376.2/332.1 respectively. This method was adopted to monitor the plasma concentration of voriconazole in tuberculosis patients of the hospital. Results: Voriconazole within the concentration range of 0.10-21.7 μg/mL was in good linear relationship with the relative peak area (r=0.993 1), and the relative standard deviation (RSD) of stability, extraction recovery rate, and matrix effect was less than 6%. Conclusion: The method based on UPLC-MS/MS can determine the concentration of voriconazole in human blood in an easy, quick and accurate manner, providing a strong basis for the safety and effectiveness of medication in patients with fungal infection.
  • Mining and Analysis of Risk Signals of Hepatobiliary System Adverse Events Caused by Anti-tuberculosis Drugs Based on FAERS*1
    WANG Yu, LI Jia, HE Qiu-yi, YAN Jia-jia, CHEN Jie
    2023, 20(10): 1081-1088. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0015
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To mine the risk signals of hepatobiliary system related adverse drug events (ADEs) caused by anti-tuberculosis drugs based on FDA adverse event reporting system (FAERS), so as to provide reference for the safe clinical use of anti-tuberculosis drugs. Methods: ADE reports with anti-tuberculosis drugs as the primary suspected drugs were extracted from the first quarter of 2004 to the first quarter of 2023 in FAERS, and ADE risk signals of anti-tuberculosis drugs were mined by using the reporting odds ratio (ROR) method and proportional reporting ratio (PRR) method. Results: ADE reports of anti-tuberculosis drugs involved 26 system organ classes (SOC). A total of 40 preferred terms (PT) related to the hepatobiliary system were detected, and 11 high level terms (HLT) were involved. There were more ADE reports related to the hepatobiliary system for rifampin (1 507 reports, 35 signals), isoniazid (932 reports, 31 signals), and pyrazinamide (331 reports, 17 signals), and the RORs leading to acute liver failure were 50.5 (95% CI: 42.4~60.2), 64.0 (95% CI: 51.9~79.0), 166.0 (119.3~230.9) respectively; there were fewer ADE reports related to the hepatobiliary system for ethambutol, rifabutin and rifapentine with lower risks. Conclusion: Anti-tuberculosis drugs have a higher risk of hepatotoxicity. When multiple anti-tuberculosis drugs are used in combination in clinical practice, special attention should be paid to the adverse effects of rifampin, isoniazid and pyrazinamide on liver functions.
  • Clinical Treatment Analysis and Related Literature Review of Two Patients with Severe Thrombocytopenia Caused by Anti-tuberculosis Drugs
    ZHU Ming, SHI Li, GAO Zhi, PEI Yi
    2023, 20(10): 1089-1093. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0016
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Anti-tuberculosis drugs are essential for prevention and treatment of tuberculosis, but medication is complex in anti-tuberculosis treatment, resulting in adverse drug reactions from time to time. However, adverse drug reactions are not only disturb the anti-tuberculosis treatment for patients, but may even endanger their lives in severe cases. This article reports the clinical treatment process of two patients with severe thrombocytopenia caused by anti-tuberculosis drugs, and reviews relevant literature at home and abroad, making a detailed analysis of clinical characteristics, treatment methods, and prognosis of the patients, so as to provide reference for the prevention and treatment in similar situations.
  • Case Analysis of Severe Vomiting Caused by Anti-Tuberculosis Drugs and Related Literature Review*1
    DU Yan, ZHOU Liang, HUANG Li, WEN Long, LIU Xiao-hui
    2023, 20(10): 1094-1098. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0017
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    The treatment of tuberculosis often requires the simultaneous use of multiple anti-tuberculosis drugs, which undoubtedly increases the probability of adverse drug reactions (ADRs). Mild ADRs caused by anti-tuberculosis drugs can interfere with the standard treatment of patients with tuberculosis, and severe ADRs can cause damage to visceral organs or even threaten the patient's life. This article reports the clinical characteristics and management of 2 patients with severe vomiting caused by anti-tuberculosis drugs. Through review on the domestic and foreign literature, the influencing factors and management measures of gastrointestinal reactions such as nausea and vomiting induced by anti-tuberculosis drugs, and the subsequent anti-tuberculosis treatment strategies are analyzed in depth so as to provide reference for the prevention and treatment of similar situations.
  • Case Report of One Patient with Eosinophilic Gastroenteritis Misdiagnosed as Abdominal Tuberculosis
    PENG Yu-jing, HU Qing-liang, YAN Xiao-feng
    2023, 20(10): 1099-1102. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0018
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the clinical data of one patient with eosinophilic gastroenteritis misdiagnosed as abdominal tuberculosis, and understand the clinical characteristics and diagnosis methods of eosinophilic gastroenteritis, so as to reduce the misdiagnosis. Methods: A retrospective analysis was performed on the diagnosis and treatment process of one patient with eosinophilic gastroenteritis misdiagnosed as abdominal tuberculosis, and the clinical characteristics, diagnosis and treatment methods, treatment measures and clinical efficacy of the disease were summarized combined with relevant literature. Results: The patient had main clinical manifestations of abdominal distension and persistent peritoneal effusion. The imaging changes revealed intestinal lesions and the endoscopy showed ileocecal lesions. In the early stage of the disease, it was considered as abdominal tuberculosis, and the diagnostic anti-tuberculosis treatment was given, but no sustained efficacy was achieved; the patient's clinical symptoms gradually worsened, and the endoscopy was performed again. The pathological biopsy showed eosinophil infiltration, and the patient was diagnosed as eosinophilic gastroenteritis. After glucocorticoid treatment, the patient's clinical symptoms were relieved quickly. Conclusion: The clinical manifestations of eosinophilic gastroenteritis are diverse and early diagnosis is difficult. When the anti-tuberculosis treatment is not effective, especially when the blood routine test shows increased count of eosinophils, it is possibly eosinophilic gastroenteritis. The pathological biopsy can confirm the diagnosis and glucocorticoids can be used to treat this disease effectively.
  • Analysis of Clinical Diagnosis and Treatment of One Case with Pulmonary Cryptococcosis Misdiagnosed as Pulmonary Tuberculosis*1
    FAN Xin-xin, WU Di, LIN You-fei, CHEN Xiao-hong, LIU Jia-fu
    2023, 20(10): 1103-1107. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0019
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To investigate the clinical diagnosis and treatment characteristics of one case with pulmonary cryptococcosis misdiagnosed as pulmonary tuberculosis, and conduct literature review to provide reference for improving the understanding of pulmonary cryptococcosis. Methods: The patient was admitted to the hospital for treatment since pulmonary shadows were found during physical examination. The chest CT examination in another hospital showed "multiple patchy shadows with blurred edges in the upper lobe of the right lung, and a few patchy and speckled blurry shadows in the anterior basal segment of the lower lobe of the right lung", so the patient was clinically diagnosed with secondary tuberculosis. Results: After admission, the patient received the examinations, but the bronchoscopy showed no obvious abnormalities, and the tuberculin purified protein derivative (PPD) test showed negative results, so the diagnosis of pulmonary tuberculosis was ruled out; a transbronchial lung biopsy (TBLB) was performed. The lung tissues were taken for special staining, and the results were positive for methenamine silver staining and for mucicarmine staining. A small amount of fungal capsules were visible, which was consistent with the characteristics of cryptococcal infection, so fluconazole was given and and the patient's symptoms improved. Conclusion: For nodular pulmonary lesions, attention should be paid to the site of onset and the halo signs that are easily ignored, which are more common in the early stages of pulmonary mycosis. The clinical symptoms and imaging manifestations of pulmonary cryptococcosis are non-specific. When the lung lesions are mainly nodules and are located in the posterior segment of the upper lobe apex and the dorsal segment of the lower lobe, they are easily misdiagnosed as pulmonary tuberculosis. A definite diagnosis depends on the results of etiological examination and pathological biopsy.
  • Detection Analysis of Gene Mutation Sites of Rifampin- or Isoniazid-resistant Mycobacterium Tuberculosis Based on Gene Chip Technology*1
    SUN Qing, SONG Hua-feng, HUANG Fan
    2023, 20(10): 1108-1112. https://doi.org/10.13493/j.issn.1672-7878.2023.10-0020
    Abstract ( ) Download PDF ( )   Knowledge map   Save
    Objective: To analyze the detection on gene mutation sites of rifampin- or isoniazid-resistant Mycobacterium tuberculosis (MTB) with the gene chip technology, so as to provide a basis for the clinical diagnosis of multidrug-resistant tuberculosis. Methods: Sputum specimens from 395 tuberculosis patients treated in the Fifth People's Hospital of Suzhou from 2020 to 2023 were collected, and the gene chip technology was utilized to detect the mutation sites of rifampin resistance gene ropB (511, 513, 516, 526, 531, 533) and isoniazid resistance genes KatG (315) and inhA (-15). By using the Roche solid culture absolute concentration method as the gold standard, the accuracy of the gene chip technology on MTB resistance to rifampin or isoniazid was analyzed. Results: The Kappa value of the gene chip technology for the diagnosis of rifampin resistance was 0.80, the coincidence rate was 92.15%, the sensitivity was 87.74%, the specificity was 93.77%, the positive predictive value was 83.78%, and the negative predictive value was 95.42%. The Kappa value of the gene chip technology for the diagnosis of isoniazid resistance was 0.87, the coincidence rate was 93.42%, the sensitivity was 98.82%, the specificity was 89.38%, the positive predictive value was 87.43%, and the negative predictive value was 99.02%. Conclusion: The gene chip technology can detect the gene mutations of MTB resistance to rifampin and isoniazid in a rapid and efficient manner, which is highly consistent with the Roche solid culture absolute concentration method and can provide a basis for the clinical diagnosis and treatment.